About Alcresta Therapeutics

Steve Dubin is currently a principal at SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health, wellness and nutritional products markets. Mr. Dubin is also the former chief executive officer of Martek Biosciences Corporation, a leader in long-chain polyunsaturated (LCPUFA) nutritional products. Mr. Dubin played a key role in developing Martek’s business from an R&D company to a fully integrated, profitable, commercial organization with more than $470 million in annual sales. He served in a variety of positions during 14 years with the company before his election to chief executive officer in July 2006, and served in that capacity until the sale of the company to Royal DSM in 2011 for approximately $1.1 billion. Mr. Dubin holds a B.S. from the University of Maryland, College Park and a J.D. from the National Law Center at the George Washington University.

Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer Venture Partners since 2004 and focuses on the healthcare sector. Mr. Kraus has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec; Verastem (NASDAQ: VSTM); and Restore Medical (NASDAQ: REST, acquired by Medtronic). He currently sits on the boards of Verastem, Allena Pharmaceuticals, Alcresta, Liazon and OvaScience, and is actively involved in BVP’s investments in Acceleron and Proteon. Prior to joining Bessemer, Mr. Kraus was a director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and operations director for the Democratic nominee for governor of Massachusetts. Mr. Kraus graduated summa cum laude with a B.A. from Yale University and earned his M.B.A. from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA), the Achievement Network, and Interise.

Alexey Margolin, Ph.D. is an experienced biotech entrepreneur, inventor, and CEO.  He co-founded and served as CEO of several biotech companies with focus on rare and metabolic diseases, such as  Alcresta Therapeutics, Allena Pharmaceuticals, and Alnara Pharmaceuticals (acquired by Eli Lilly in 2010). He is currently Chairman of the Board of Synspira Therapeutics. Earlier in his career Dr. Margolin served as chief scientific officer of Altus Pharmaceuticals where he initiated and led several therapeutic programs based on orally-administered proteins. He is the author of more than 60 publications and is an inventor on numerous patents including invention of the lead Alcresta product RELiZORB for enteral feeding.

Dr. Margolin holds both his M.S. in chemistry and Ph.D. in bio-organic chemistry from Moscow University.

Dr. Muney is currently a senior healthcare advisor for Pritzker Private Capital, Arsenal Capital, Bain Management Consulting, and NEA Venture capital.

Previously Dr. Muney served as Cigna’s Chief Medical Officer and Executive Vice President of Total Health and Network.  In his role as Chief Medical Officer, Dr. Muney was responsible for Cigna’s clinical strategy and policy, health advocacy programs, coverage policy, and quality measurement and improvement.  As lead for Total Health and Network, Dr. Muney was responsible for the market medical and clinical nurse executives, total health physician operations, total health clinical operations, and dental clinical operations, as well as medical, behavioral, and dental contracting.  Dr. Muney also oversaw Cigna’s team of doctors, dentists, nurses, and behavioral health clinicians involved in the company’s health management and wellness programs.

Before joining Cigna, Dr. Muney was an Executive Director in the Private Equity Group at The Blackstone Group, and the CEO of Equity Healthcare, which he founded to manage the healthcare costs of Blackstone’s portfolio companies.  While at Blackstone, he also served on the Board of Directors of Vanguard Health System and Team Health.  Prior to Blackstone, Alan was the Executive Vice President and Chief Medical Officer of Oxford Health Plans and Chief Medical Officer of United Healthcare of the Northeast region from 1998-2007.

Dr. Muney is board-certified in pediatrics, and received his B.S. in Biology and his Doctor of Medicine degrees from Brown University, and a Masters in Health Administration from the University of La Verne.

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics.  He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics.  Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme.  During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development.   Before joining Vericel, Daniel was one of Takeda North America’s early employee’s and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories.  Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.

Mr. Sen joined Athyrium in 2015 as a partner. At Athyrium, Mr. Sen focuses on growth equity, private equity and special situations investing across the healthcare ecosystem.

Before joining Athyrium, Mr. Sen spent eight years as a senior investment professional and a founding member of the special-situations / distressed group at Littlejohn & Co. Mr. Sen specialized in investments in control and non-control opportunities and creative financings across a variety of industries, including healthcare, business services, energy and industrial manufacturing. He led all aspects of the firm's investment evaluation process from sourcing to executing to exiting such investments. Mr. Sen has significant experience across the spectrum of fixed income, including new issue financings, secondary trading opportunities, rescue lending, out-of-court restructurings, prepackaged bankruptcies and Chapter 11 proceedings.

Prior to this role, Mr. Sen was a Senior Associate in the private equity group at Littlejohn & Co. During his time at Littlejohn, Mr. Sen was responsible for evaluating and executing middle-market investment opportunities.

Mr. Sen began his career at J.P. Morgan Securities, where he served as a financial analyst in the leveraged finance group. At J.P. Morgan Securities, he was involved in a variety of transactions, including leveraged buyouts, acquisition financings and corporate restructurings.

Mr. Sen received an A.B. in economics from Dartmouth College in 2000.